CV Sciences (OTCMKTS:CVSI) posted its earnings results on Tuesday. The company reported $0.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.01, Morningstar.com reports. The business had revenue of $14.22 million for the quarter, compared to analyst estimates of $14.91 million. CV Sciences had a net margin of 20.73% and a return on equity of 45.78%.
CV Sciences stock opened at $4.74 on Thursday. The company has a market cap of $458.22 million, a P/E ratio of 52.67 and a beta of -0.74. CV Sciences has a 1-year low of $0.40 and a 1-year high of $9.20.
Separately, Northland Securities reaffirmed a “buy” rating and set a $8.00 target price on shares of CV Sciences in a report on Wednesday.
CV Sciences Company Profile
CV Sciences, Inc operates as a life science company. It operates through two segments, Specialty Pharmaceuticals and Consumer Products. The company focuses on developing and commercializing prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.
Featured Article: The Structure of a Futures Contract
Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.